Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real ‐world analysis

ConclusionNCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed.

Source: Thoracic Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Yao Zhang, Huiting Li, Bo Yu, Si Sun, Zhihuang Hu, Xianghua Wu, Yang Zhang, Bin Li, Yawei Zhang, Jiaqing Xiang, Jialei Wang, Hui Yu Tags: ORIGINAL ARTICLE Source Type: research